Compare MAMA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAMA | TECX |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.5M | 554.1M |
| IPO Year | 2011 | N/A |
| Metric | MAMA | TECX |
|---|---|---|
| Price | $14.31 | $28.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $19.00 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 344.7K | 215.2K |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $31.09 | N/A |
| Revenue Next Year | $16.12 | N/A |
| P/E Ratio | $108.31 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $6.53 | $14.39 |
| 52 Week High | $17.85 | $35.99 |
| Indicator | MAMA | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 47.94 |
| Support Level | $12.86 | $27.39 |
| Resistance Level | $14.88 | $31.42 |
| Average True Range (ATR) | 0.66 | 1.89 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 71.77 | 45.57 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.